Concerns about a potential revenue decline due to the absence of deferred revenue related to divested asset Toctino were allayed when Basilea reported H1/2019 revenue growth of 5.5% YoY, driven by strong contributions from antifungal Cresemba. Our 2019E estimates are broadly unchanged and in line with tightened financial guidance. Changes for 2020E and beyond reflect multiple adjustments including the impact of Pfizer taking over manufacturing of Cresemba in its territory during 2020E. We tri
29 Aug 2019
Cresemba on track, oncology pipeline advances
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cresemba on track, oncology pipeline advances
Basilea Pharmaceutica AG (0QNA:LON) | 4,620 0 0.0% | Mkt Cap: 605.3m
- Published:
29 Aug 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
13
Concerns about a potential revenue decline due to the absence of deferred revenue related to divested asset Toctino were allayed when Basilea reported H1/2019 revenue growth of 5.5% YoY, driven by strong contributions from antifungal Cresemba. Our 2019E estimates are broadly unchanged and in line with tightened financial guidance. Changes for 2020E and beyond reflect multiple adjustments including the impact of Pfizer taking over manufacturing of Cresemba in its territory during 2020E. We tri